{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 2078, "pageSize": 30, "pageCount": 10666, "rows": [ { "docId": "019dd923-5efe-75c0-8dfe-c33214992e60", "docSlug": "e4e961afe28a39dc", "documentTitle": "2026 Investor Deck", "authorId": "JPMorgan-IR", "authorName": "Summit Therapeutics", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.778, "pageNumber": 8, "slideType": "case_study", "function": "illustrate_case", "notes": "The slide uses a structured grid to compare four distinct clinical trial programs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c33214992e60/8", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60#slide-8", "loopMatches": [ { "to": 15, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "79e0c4c9-6f51-444c-a54b-594ca0500180", "evidence": "The deck implies the cost of inaction through its emphasis on Ivonescimab's development progress and potential", "position": 0, "objective": "Highlighting the importance of timely progress in biopharma development", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 11, "from": 4, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "8d8d3398-4ad3-42b9-8a45-5223f61f6fa3", "evidence": "Slides 4-11 focus on Ivonescimab's clinical achievements and potential", "position": 1, "objective": "Positioning Ivonescimab as a high-potential therapy", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.7, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c33214992e60", "docSlug": "e4e961afe28a39dc", "documentTitle": "2026 Investor Deck", "authorId": "JPMorgan-IR", "authorName": "Summit Therapeutics", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.778, "pageNumber": 9, "slideType": "data_table", "function": "quantify_impact", "notes": "The slide presents clinical trial data for Ivonescimab in NSCLC, showing consistent HR improvements across different patient populations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c33214992e60/9", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60#slide-9", "loopMatches": [ { "to": 15, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "79e0c4c9-6f51-444c-a54b-594ca0500180", "evidence": "The deck implies the cost of inaction through its emphasis on Ivonescimab's development progress and potential", "position": 0, "objective": "Highlighting the importance of timely progress in biopharma development", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 11, "from": 4, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "8d8d3398-4ad3-42b9-8a45-5223f61f6fa3", "evidence": "Slides 4-11 focus on Ivonescimab's clinical achievements and potential", "position": 1, "objective": "Positioning Ivonescimab as a high-potential therapy", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.7, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c33214992e60", "docSlug": "e4e961afe28a39dc", "documentTitle": "2026 Investor Deck", "authorId": "JPMorgan-IR", "authorName": "Summit Therapeutics", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.778, "pageNumber": 10, "slideType": "timeline", "function": "summarize", "notes": "The slide uses a dual-column timeline layout to track progress of various HARMONI clinical trials.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c33214992e60/10", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60#slide-10", "loopMatches": [ { "to": 15, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "79e0c4c9-6f51-444c-a54b-594ca0500180", "evidence": "The deck implies the cost of inaction through its emphasis on Ivonescimab's development progress and potential", "position": 0, "objective": "Highlighting the importance of timely progress in biopharma development", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 11, "from": 4, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "8d8d3398-4ad3-42b9-8a45-5223f61f6fa3", "evidence": "Slides 4-11 focus on Ivonescimab's clinical achievements and potential", "position": 1, "objective": "Positioning Ivonescimab as a high-potential therapy", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.7, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c33214992e60", "docSlug": "e4e961afe28a39dc", "documentTitle": "2026 Investor Deck", "authorId": "JPMorgan-IR", "authorName": "Summit Therapeutics", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.778, "pageNumber": 11, "slideType": "key_takeaways", "function": "summarize", "notes": "The slide uses a checkmark visual to indicate positive outcomes for each clinical question posed.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c33214992e60/11", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60#slide-11", "loopMatches": [ { "to": 15, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "79e0c4c9-6f51-444c-a54b-594ca0500180", "evidence": "The deck implies the cost of inaction through its emphasis on Ivonescimab's development progress and potential", "position": 0, "objective": "Highlighting the importance of timely progress in biopharma development", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 11, "from": 4, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "8d8d3398-4ad3-42b9-8a45-5223f61f6fa3", "evidence": "Slides 4-11 focus on Ivonescimab's clinical achievements and potential", "position": 1, "objective": "Positioning Ivonescimab as a high-potential therapy", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.7, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c33214992e60", "docSlug": "e4e961afe28a39dc", "documentTitle": "2026 Investor Deck", "authorId": "JPMorgan-IR", "authorName": "Summit Therapeutics", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.778, "pageNumber": 12, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a timeline framework to communicate upcoming clinical trial readouts and regulatory events.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c33214992e60/12", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60#slide-12", "loopMatches": [ { "to": 15, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "79e0c4c9-6f51-444c-a54b-594ca0500180", "evidence": "The deck implies the cost of inaction through its emphasis on Ivonescimab's development progress and potential", "position": 0, "objective": "Highlighting the importance of timely progress in biopharma development", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c33214992e60", "docSlug": "e4e961afe28a39dc", "documentTitle": "2026 Investor Deck", "authorId": "JPMorgan-IR", "authorName": "Summit Therapeutics", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.778, "pageNumber": 13, "slideType": "financial_analysis", "function": "summarize", "notes": "The slide highlights a strong liquidity position with significant cash and zero debt.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c33214992e60/13", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60#slide-13", "loopMatches": [ { "to": 15, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "79e0c4c9-6f51-444c-a54b-594ca0500180", "evidence": "The deck implies the cost of inaction through its emphasis on Ivonescimab's development progress and potential", "position": 0, "objective": "Highlighting the importance of timely progress in biopharma development", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 13, "from": 13, "beatId": "30f96b06-3487-46b3-a5f5-2bcb808d5b16", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "Slide 13 shows Strong Balance Sheet to Kick Off 2026", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c33214992e60", "docSlug": "e4e961afe28a39dc", "documentTitle": "2026 Investor Deck", "authorId": "JPMorgan-IR", "authorName": "Summit Therapeutics", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.778, "pageNumber": 14, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a visual flow to aggregate market sizes and point toward future growth areas.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c33214992e60/14", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60#slide-14", "loopMatches": [ { "to": 15, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "79e0c4c9-6f51-444c-a54b-594ca0500180", "evidence": "The deck implies the cost of inaction through its emphasis on Ivonescimab's development progress and potential", "position": 0, "objective": "Highlighting the importance of timely progress in biopharma development", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 14, "from": 14, "beatId": "42de891b-9744-41da-b920-a36806f9f97e", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "Slide 14 discusses Platform Opportunity", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c33214992e60", "docSlug": "e4e961afe28a39dc", "documentTitle": "2026 Investor Deck", "authorId": "JPMorgan-IR", "authorName": "Summit Therapeutics", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.778, "pageNumber": 15, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c33214992e60/15", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60#slide-15", "loopMatches": [ { "to": 15, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "79e0c4c9-6f51-444c-a54b-594ca0500180", "evidence": "The deck implies the cost of inaction through its emphasis on Ivonescimab's development progress and potential", "position": 0, "objective": "Highlighting the importance of timely progress in biopharma development", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 1, "slideType": "executive_summary", "function": "summarize", "notes": "Includes CEO quote and segment-specific product/category icons.", "imagePath": "https://imgproxy.kitesheet.com/hDbAjAecDCz7dkCPWlbsp7JdiCPV2yvGz5zFCyEzy3U/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wYjM0ZmY2Y2NhZDQ5MTYzL3AwMDEuanBn", "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/1", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/n1uzdlyIB3gyG7b4tZJ4BaDaNE1ZQctknoHiMMlv1OQ/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wYjM0ZmY2Y2NhZDQ5MTYzL3AwMDEucG5n", "thumbSrc": "https://imgproxy.kitesheet.com/XTZ2Dhi_DMsUsXxZOF2BMOgkLukCZyH5wlfsOCEx29U/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wYjM0ZmY2Y2NhZDQ5MTYzL3AwMDEuanBn", "thumbSrcAlt": "https://imgproxy.kitesheet.com/TkNBfpVClLTbJrjaAqXvr4Gn2RDqZBf4b4nd-8Ytjx0/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wYjM0ZmY2Y2NhZDQ5MTYzL3AwMDEucG5n" }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 2, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/2", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 3, "slideType": "appendix_disclosure", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/3", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 4, "slideType": "appendix_disclosure", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/4", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 5, "slideType": "agenda", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/5", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-5", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 6, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/6", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-6", "loopMatches": [], "arcBeatMatches": [ { "to": 13, "from": 6, "beatId": "c5bcd261-f1bb-4cf5-83f0-83b660e2064f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "team bios", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 7, "slideType": "kpi_dashboard", "function": "summarize", "notes": "The slide uses a grid of images to represent business units, with a primary metric highlighted on the left.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/7", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 7, "from": 7, "beatId": "0fc2e4c6-862d-4cb0-a043-2bdba17a216c", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "Q1 Earnings Summary", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 13, "from": 6, "beatId": "c5bcd261-f1bb-4cf5-83f0-83b660e2064f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "team bios", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 8, "slideType": "kpi_dashboard", "function": "summarize", "notes": "The slide uses a grid layout to showcase product logos under three main therapeutic pillars.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/8", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-8", "loopMatches": [], "arcBeatMatches": [ { "to": 10, "from": 8, "beatId": "d93038c2-5596-4702-965b-06487e7e5d77", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Innovative Medicine: 7.4% operational sales growth", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 13, "from": 6, "beatId": "c5bcd261-f1bb-4cf5-83f0-83b660e2064f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "team bios", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 9, "slideType": "key_messages", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/9", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 10, "from": 8, "beatId": "d93038c2-5596-4702-965b-06487e7e5d77", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Innovative Medicine: 7.4% operational sales growth", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 13, "from": 6, "beatId": "c5bcd261-f1bb-4cf5-83f0-83b660e2064f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "team bios", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 10, "slideType": "kpi_dashboard", "function": "summarize", "notes": "The slide uses a grid layout to showcase product logos under three main therapeutic pillars.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/10", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-10", "loopMatches": [], "arcBeatMatches": [ { "to": 10, "from": 8, "beatId": "d93038c2-5596-4702-965b-06487e7e5d77", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Innovative Medicine: 7.4% operational sales growth", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 13, "from": 6, "beatId": "c5bcd261-f1bb-4cf5-83f0-83b660e2064f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "team bios", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 11, "slideType": "market_landscape", "function": "summarize", "notes": "The slide uses a three-column layout to categorize products by medical specialty.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/11", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-11", "loopMatches": [], "arcBeatMatches": [ { "to": 13, "from": 6, "beatId": "c5bcd261-f1bb-4cf5-83f0-83b660e2064f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "team bios", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 12, "slideType": "thesis_headline", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/12", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 13, "from": 6, "beatId": "c5bcd261-f1bb-4cf5-83f0-83b660e2064f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "team bios", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 13, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/13", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 13, "from": 6, "beatId": "c5bcd261-f1bb-4cf5-83f0-83b660e2064f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "team bios", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 14, "slideType": "data_table", "function": "analyze_data", "notes": "The table includes a footnote regarding non-GAAP measures and currency impact.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/14", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 14, "beatId": "e490029b-28d3-4562-8e6c-4cea53784f98", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "1st Quarter 2026 sales, financial highlights, and condensed consolidated statement of earnings", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 15, "slideType": "kpi_dashboard", "function": "summarize", "notes": "The slide uses a consistent color scheme (dark blue for 2026, light blue for 2025) to compare quarterly performance.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/15", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 14, "beatId": "e490029b-28d3-4562-8e6c-4cea53784f98", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "1st Quarter 2026 sales, financial highlights, and condensed consolidated statement of earnings", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 16, "slideType": "kpi_dashboard", "function": "summarize", "notes": "Includes a donut chart showing sales breakdown by segment and a table detailing operational drivers.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/16", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-16", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 14, "beatId": "e490029b-28d3-4562-8e6c-4cea53784f98", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "1st Quarter 2026 sales, financial highlights, and condensed consolidated statement of earnings", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 17, "slideType": "kpi_dashboard", "function": "summarize", "notes": "The slide uses a donut chart to show total sales and growth, and a table-like structure to detail drivers by business unit.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/17", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-17", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 14, "beatId": "e490029b-28d3-4562-8e6c-4cea53784f98", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "1st Quarter 2026 sales, financial highlights, and condensed consolidated statement of earnings", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 18, "slideType": "data_table", "function": "analyze_data", "notes": "Includes both GAAP and non-GAAP (adjusted) financial metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/18", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-18", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 14, "beatId": "e490029b-28d3-4562-8e6c-4cea53784f98", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "1st Quarter 2026 sales, financial highlights, and condensed consolidated statement of earnings", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 19, "slideType": "data_table", "function": "analyze_data", "notes": "Includes footnotes regarding non-GAAP measures and segment allocations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/19", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-19", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 14, "beatId": "e490029b-28d3-4562-8e6c-4cea53784f98", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "1st Quarter 2026 sales, financial highlights, and condensed consolidated statement of earnings", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 20, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/20", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-20", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 21, "slideType": "financial_analysis", "function": "present_solution", "notes": "The slide uses a hierarchical flow chart to show capital allocation priorities, with R&D and dividends highlighted as specific outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/21", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-21", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5efe-75c0-8dfe-c6e16423bb4e", "docSlug": "0b34ff6ccad49163", "documentTitle": "2026 Q1 Earnings", "authorId": "Johnson-Johnson", "authorName": "Johnson & Johnson", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.647, "pageNumber": 22, "slideType": "data_table", "function": "summarize", "notes": "The table compares two sets of financial guidance projections for the same fiscal year.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c6e16423bb4e/22", "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e", "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c6e16423bb4e#slide-22", "loopMatches": [ { "to": 22, "from": 22, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "4323d622-a3cb-4574-8a96-fdb351a343ce", "evidence": "Operational sales guidance and adjusted operational EPS", "position": 0, "objective": "highlighting the importance of 2026 milestones", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }